cefepime hydrochloride / Generic mfg. - LARVOL DELTA

ANTIBIOTIC TIMING AND IMPACT ON SURVIVAL OUTCOMES IN ANTI-CD19 AND ANTI-BCMA CAR-T CELL THERAPY (EBMT 2026) - "Particularly, PIM (piperacillin-tazobactam, imipenem, meropenem) are implicated with poor outcomes...CD19 products included lisocabtagene maraleucel, tisagenlecleucel, brexucabtagene autoleucel, and axicabtagene ciloleucel. BCMA products included idecabtagene vicleucel and ciltacabtagene autoleucel...Post CAR-T antibiotics were largely fourth generation cephalosporins such as cefepime, with vancomycin... Exposure to antibiotics in 30 days pre-CAR-T is associated with worse OS, even when adjusted for age, prior lines of therapy, and infection rate. Post-CAR-T antibiotics did not have an effect on PFS, OS or progression at first PET-CT scan. Clinicians should be judicious with antibiotic exposure in the 30 days prior to CAR-T therapy."

CAR T-Cell Therapy • Acute Lymphocytic Leukemia • B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma

MANAGEMENT OF BLOODSTREAM INFECTION SECONDARY TO BACTERIAL TRANSLOCATION DURING THE NEUTROPENIC PHASE OF STEM CELL TRANSPLANT. A NO–CENTRAL LINE REMOVAL STRATEGY IN 73 EPISODES (EBMT 2026) - "In each episode of fever and neutropenia, a set of blood cultures was obtained, and empiric antibiotic (meropenem or ceftazidime/avibactam) was initiated within the first hour. Later, the therapy was de-escalated to cefepime according to the results and evolution... 1-More than 50% of bacteremia occurring during the neutropenic phase of SCT meet the CDC criteria of MBI-LCBI.2- Given that the central line (CL) is not the source of the infection, a strategy involving early initiation of antibiotics and salvage of the catheter is feasible and seems safe.3- This strategy saves resources and avoids invasive procedures in patients at risk of complicationsReference: (1) CDC. NHSN Patient Safety Component Manual: CLABSI. https://www.cdc.gov/nhsn/pdfs/pscmanual/4psc_clabscurrent.pdf"

Cardiovascular • Febrile Neutropenia • Hematological Disorders • Infectious Disease • Neutropenia • Thrombosis • Transplantation

CANADIAN SURVEY ON ANTIBACTERIAL PROPHYLAXIS AND FEBRILE NEUTROPENIA MANAGEMENT IN ADULT ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS (EBMT 2026) - "Piperacillin–tazobactam was the most frequently used empirical therapy across centers (n=10); while one center used cefepime. Considerable heterogeneity exists in antibacterial prophylaxis strategies across Canadian allo-HCT programs, with the majority opting against routine universal prophylaxis. Empirical management of FN was largely uniform, with piperacillin–tazobactam as the preferred agent. Importantly, while antibacterial prophylaxis may reduce early infectious complications, potential harms—including antimicrobial resistance, Clostridioides difficile infection, and disruption of the gut microbiome—must be weighed against uncertain benefits on survival outcomes."

Clinical • Bone Marrow Transplantation • Febrile Neutropenia • Hematological Disorders • Infectious Disease • Neutropenia • Transplantation

SAFETY OF OMITTING ANTIBACTERIAL PROPHYLAXIS IN ADULT ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: EXPERIENCE FROM A SINGLE CANADIAN CENTER (EBMT 2026) - "Outcomes included FN rates, bacteremia, bacterial distribution, infection-related mortality (IRM), acute GVHD (including GI involvement), use of carbapenems or vancomycin, and C. difficile infection. In this alloHCT cohort managed without pATB, FN rates, and bacteremia were within expected ranges and effectively managed with cefepime. Fluoroquinolone resistance was found in 25,9% of gram-negative bacteriemia. Many C. difficile infections occurred independently of antibiotic exposure."

Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Febrile Neutropenia • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Leukemia • Liver Failure • Lymphoma • Neutropenia • Transplantation

Definitive cefepime versus carbapenems for bacteremia caused by Enterobacterales with a risk of chromosomal AmpC production in children. (PubMed, J Infect Chemother) - "Cefepime and meropenem as definitive therapy demonstrated comparable outcomes for AmpC-E bacteremia. Further prospective studies are warranted."

Journal • Infectious Disease • Pediatrics

A Case of Fatal Cupriavidus gilardii Sepsis Following Cord Blood Transplantation: Pitfalls of Novel Antimicrobial Agents. (PubMed, Int J Infect Dis) - "Cefiderocol (CFDC) is a novel antimicrobial agent that exhibits activity against carbapenem-resistant non-fermenting gram-negative bacilli, such as resistant Pseudomonas aeruginosa and Stenotrophomonas maltophilia, and has thus attracted considerable attention. Herein, we report a case in which a patient who was undergoing cord blood transplantation developed gram-negative rod sepsis after meropenem administration...The causative organism was later identified as Cupriavidus gilardii, which was resistant to novel antimicrobial agents, including CFDC, ceftazidime/avibactam, and ceftolozane/tazobactam. However, it was susceptible to cefepime and cefotaxime, suggesting a potential pitfall in the sole reliance on novel antibacterial drugs...This is the first reported case in the context of hematopoietic cell transplantation and the second diagnosed case using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Moreover, this report presents a..."

Journal • Hematological Disorders • Infectious Disease • Neutropenia • Septic Shock • Transplantation

Rational engineering of the R2-loop region of the PDC β-lactamase reveals a major impact on resistance to cefepime and cefiderocol in Pseudomonas aeruginosa (ESCMID Global 2026) - No abstract available

Characterization of a conjugative IncFII/IncR plasmid harboring blaKPC-2 in a clinical ST91 Citrobacter freundii isolate. (PubMed, BMC Microbiol) - "To our knowledge, this is the first characterization of an IncFII(pBK30683)/IncR plasmid carrying blaKPC-2 in a clinical C. freundii ST91 isolate. The findings highlight plasmid lineages as drivers of carbapenem resistance dissemination and underscore the need for plasmid-focused genomic surveillance, particularly for monitoring transferable resistance vehicles across clinically relevant hosts."

Journal

Efficacy and safety of cefepime/nacubactam and aztreonam/nacubactam compared with imipenem/cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis: integral-1, a double-blind, randomised phase III trial (ESCMID Global 2026) - No abstract available

Clinical • P3 data • Infectious Disease • Nephrology

The in vitro activity of aztreonam/nacubactam and cefepime/nacubactam against molecularly characterised Enterobacterales isolates including those with ceftazidime-avibactam and aztreonam/avibactam resistance mechanisms collected globally from 2021-2023 (ESCMID Global 2026) - No abstract available

Preclinical

Exploring carbapenem-sparing strategies: in vitro susceptibility analysis of temocillin and cefepime against Enterobacterales bloodstream isolates (ESCMID Global 2026) - No abstract available

Preclinical

Activity of the novel combination therapy cefepime/nacubactam against 17,220 clinical isolates of Enterobacterales collected worldwide during 2021-2024 (ESCMID Global 2026) - No abstract available

Clinical • Combination therapy

Outcomes of cefepime/nacubactam and aztreonam/nacubactam in cUTI/AP patients with ESBL-producing bacteria enrolled into prospective phase III randomised clinical study (Integral-1) (ESCMID Global 2026) - No abstract available

Clinical • P3 data

Population pharmacokinetic analysis of nacubactam, cefepime, and aztreonam and exposure–response analysis of efficacy results from phase III clinical trials (ESCMID Global 2026) - No abstract available

Clinical • P3 data • PK/PD data

In vivo activity of cefepime/sulbactam in the Galleria mellonella invertebrate infection model (ESCMID Global 2026) - No abstract available

Preclinical • Infectious Disease

Outcomes of cefepime/nacubactam and aztreonam/nacubactam for treatment of cUTI/AP patients with CRE: subgroup analysis of integral-1 study (ESCMID Global 2026) - No abstract available

Clinical

Determination of the nonclinical PK/PD target value for nacubactam in a mouse thigh infection model using carbapenem-resistant Enterobacterales under co-administration of cefepime or aztreonam (ESCMID Global 2026) - No abstract available

PK/PD data • Preclinical • Infectious Disease

Probability of target attainment of cefepime/nacubactam and aztreonam/nacubactam for carbapenem-resistant Enterobacterales infections (ESCMID Global 2026) - No abstract available

Infectious Disease

Efficacy and safety of cefepime/nacubactam and aztreonam/nacubactam vs best available therapy in adults with cUTI/AP, HABP/VABP, cIAI due to carbapenem resistant Enterobacterales: integral-2, single-blind, randomised phase III trial (ESCMID Global 2026) - No abstract available

Clinical • P3 data

Neurologic Manifestations of Renal and Electrolyte Disorders. (PubMed, Continuum (Minneap Minn)) - "Cefepime neurotoxicity in patients with renal failure is increasingly recognized...Hyponatremia is the only electrolyte abnormality associated with irreversible brain injury. Neuroimaging should be considered in patients with acute renal failure and encephalopathy to evaluate for posterior encephalopathy syndrome or subdural hematoma."

Journal • Review • Acute Kidney Injury • Cardiovascular • CNS Disorders • Epilepsy • Heart Failure • Nephrology • Renal Disease • Vascular Neurology

Clinical characteristics of pediatric Moraxella bacteremia in a children's hospital. (PubMed, Pediatr Int) - "The patients with bacteremia due to M. osloensis or M. catarrhalis had favorable clinical outcomes."

Journal • Observational data • Retrospective data • Critical care • Glomerulonephritis • Infectious Disease • Nephrology • Pediatrics • Pneumonia • Renal Disease • Respiratory Diseases

Beta-lactam Antibiotic Cefepime Attenuates Lipopolysaccharide-induced Pain and Depression By Modulating Inflammatory Response and Astroglial Glutamate Transporter in Mice. (PubMed, J Neuroimmune Pharmacol) - No abstract available

Journal • Preclinical • CNS Disorders • Depression • Inflammation • Mood Disorders • Pain • Psychiatry

First report of extended-spectrum beta lactamase (ESBL) and carbapenemase-producing MDR Klebsiella pneumoniae from Fuchka. (PubMed, PLoS One) - "All showed resistance to amoxicillin and cefuroxime (100%), while most were sensitive to cefepime (96.7%), norfloxacin (96.7%), imipenem (93.3%) and meropenem (83.3%). Moreover, other resistance determinants (aadA1, aac3IV was most prevalent (40%) but aadA1, qnrA were not detected. The presence of multidrug-resistant, ESBL- and carbapenemase-producing K. pneumoniae in fuchka represents a critical threat to public health."

Journal • Infectious Disease • Pneumonia

Coexistence with Staphylococcus aureus modulates the virulence and antibiotic resistance of Pseudomonas aeruginosa. (PubMed, Ann Clin Microbiol Antimicrob) - "Finally, in vitro investigations for antibiotic resistance and virulence production clearly demonstrated a synergistic interaction between P. aeruginosa and S. aureus in the co-existence mixture. Compared to P. aeruginosa mono-cultures, the co-cultured strains exhibited enhanced resistance profiles and increased expression of key virulence factors, indicating that the simultaneous presence of both species promotes mutual adaptation and potentiation of pathogenic traits. Additionally, in vivo experiments confirmed that the co-infection with S. aureus significantly enhanced the pathogenicity of P. aeruginosa, as indicated by increased mortality rates and higher bacterial counts in lung tissues. Altogether, our results shed light on the impact of the co-existence of microbial species on bacterial virulence and antibiotic resistance."

Journal • Infectious Disease • ELANE

Epidemiology of Healthcare-Associated Infections Caused by Multidrug-Resistant Bacteria and Antimicrobial Resistance Patterns in a Romanian Tertiary Care Hospital. (PubMed, J Clin Med) - "Microbiological analysis of MDR isolates (n = 406) revealed consistently high resistance rates to ciprofloxacin, cefepime, and ceftazidime, exceeding 95% in 2023-2024, while resistance to carbapenems surpassed 90% by the end of the study period. The dominance of carbapenem-resistant A. baumannii and extended-spectrum beta-lactamase-producing and carbapenem-resistant Klebsiella spp. highlights the urgent need for strengthened antimicrobial stewardship, enhanced microbiological surveillance, and reinforced infection prevention strategies."

Journal • Critical care • Infectious Disease • Pneumonia